Cramer said adding up all of Warnaco's assets would take shares dramatically higher than where they trade today. He only hopes company management is listening.
Here's what Cramer had to say about callers' stocks during the "Lightning Round":
: "I like Lululemon. They are a well-run company."
Magnum Hunter Resources
: "This is a spec on oil going back to $120. That's where this stock would hit a new all-time high."
: "This is part of a complex that's being sold. That's a mistake. They should be bought right here."
Hain Celestial Group
: "Hain did a good job and delivered. I like that story."
: "I want you to be big in Wells Fargo. They have 30% of America's mortgage market. Pull the trigger right here."
: "It's good, but
is the best. I'm going to say don't buy and wait for a pullback."
Cobalt International Energy
: "It's still up for the year but oil has to go up big for it to work. Let's wait for crude to comeback, then this stock will come back."
: "I like their acquisition. I want to pull the trigger tomorrow."
: "People don't like aerospace, but that's wrong. I think under $80 you have a big opportunity."
In the middle of this year's conference season, Cramer highlighted what he called his favorite one of the year, the UBS Global Life Sciences Conference, which gets under way Wednesday. He provided viewers with a outline of what to expect during the presentations, which are usually available via webcast.
(AGN - Get Report)
remains a favorite and he's anxious to hear about the company's new indications for Botox and get an update on its pipeline of new products.
(GILD - Get Report)
will also be presenting, and Cramer said that stock is not done going higher despite its recent 10% move up.
Cramer was also bullish on
(CELG - Get Report)
, another favorite biotech with a terrific pipeline of new drugs on the way.
Cramer was less enthusiastic about
, three companies that have become too hot to handle.
As a speculative play, Cramer noted
, a stock that's up 25% for the year. He said the company's two orphan drugs should be receiving news next month, so there's no hurry for investors to buy in on Wednesday's presentation.